Cotinga Pharmaceuticals EV/EBITDA
¿Qué es el EV/EBITDA de Cotinga Pharmaceuticals?
El EV/EBITDA de Cotinga Pharmaceuticals, Inc. es N/A
¿Cuál es la definición de EV/EBITDA?
EV / EBITDA es el valor de la empresa dividido por las ganancias antes de intereses, impuestos, depreciación y amortización. Es una medida de cuál cara es una acción y es más frecuentemente válida para comparaciones entre compañías que la relación precio / ganancias. Mide el precio (en forma de valor empresarial) que un inversionista paga en beneficio del flujo de caja de la compañía (en forma de EBITDA).
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV/EBITDA de compañías en Sector Health Care en TSXV en comparadas con Cotinga Pharmaceuticals
¿Qué hace Cotinga Pharmaceuticals?
Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.
Empresas con ev/ebitda similar a Cotinga Pharmaceuticals
- Adrabbit tiene EV/EBITDA de N/A
- Chipotle Mexican Grill tiene EV/EBITDA de N/A
- Azarga Metals tiene EV/EBITDA de N/A
- redT energy plc tiene EV/EBITDA de N/A
- Astra tiene EV/EBITDA de N/A
- Shield Therapeutics Plc tiene EV/EBITDA de N/A
- Cotinga Pharmaceuticals tiene EV/EBITDA de N/A
- Cubicfarm Systems Corp tiene EV/EBITDA de N/A
- LQwD FinTech tiene EV/EBITDA de N/A
- CBK tiene EV/EBITDA de N/A
- Rich Goldman tiene EV/EBITDA de N/A
- Englobal tiene EV/EBITDA de N/A
- Aurelius Minerals tiene EV/EBITDA de N/A